UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s What Happened

by · The Markets Daily

UCB SA (OTCMKTS:UCBJF – Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $236.49, but opened at $254.09. UCB shares last traded at $235.66, with a volume of 34 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Check Out Our Latest Analysis on UCBJF

UCB Stock Down 3.4%

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company’s fifty day moving average price is $260.58 and its 200-day moving average price is $283.62.

UCB Company Profile

(Get Free Report)

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.

See Also